Yanjun Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yanjun Li has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Yuyang Gu
Department of Oncology, The First Hospital of Jiaxing, Jiaxing, PR China
2 shared publications - Qijun Li
Department of Oncology, The First Hospital of Jiaxing, Jiaxing, PR China
1 shared publication - Tingting Qian
Department of Oncology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, People’s Republic of China
1 shared publication - Xiaofang Xu
The First Hospital of Jiaxing & The Affiliated Hospital of Jiaxing University Jiaxing China
1 shared publication - Yefan Zhang
Department of Cardiothoracic Surgery, The First Hospital of Jiaxing, Jiaxing, PR China
1 shared publication - Yufen Xu
Zhejiang Chinese Medical University
1 shared publication
Latest Publications
- Open Access
- 16 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
High TRA2B expression mediated by ncRNA correlates with adverse outcomes and tumor immune infiltration in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most frequent diagnosed malignancies globally with dismalprognosis and high mortality. Transformer 2 beta homolog (TRA2B), known as serine/arginine-rich splicing factor 10 (SRSF10), is a member of the serine/arginine (SR) protein superfamily that modulates gene expression by regulating mRNA splicing. The significance of TRA2B in cancer has received considerable attention in recent years, however, its specific role and molecular mechanisms in HCC remain unknown. This study aimed to analyze the expression of TRA2B in LIHC with the support of integrative bioinformatic analysis. The study conducted Kaplan-Meier and cox regression analyses and showed that the upregulated TRA2B was notably correlated with the dismal prognosis in HCC. TRA2B was identified as a potential proto-oncogene in HCC associated with poor prognosis. TRA2B expression in tumor tissues was found to be elevated using bioinformatics analysis. Following that, non-coding RNAs (ncRNA) related to TRA2B were extracted using series analysis. The CRNDE/LINC00511-miR-29c-3p axis was characterized as a potential upstream ncRNA-correlated signaling of TRA2B in HCC. Subsequently, the role of TRA2B in the tumor immune microenvironment (TIME) was investigated. In summary, this research provides novel insight into the potential role of TRA2B across various cancers and indicated that ncRNA-mediated overexpression of TRA2B is associated with the dismal prognosis in HCC.
- 16 December 2025
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessHigh TRA2B expression mediated by ncRNA correlates with adverse outcomes and tumor immune infiltration in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most frequent diagnosed malignancies globally with dismalprognosis and high mortality. Transformer 2 beta homolog (TRA2B), known as serine/arginine-rich splicing factor 10 (SRSF10), is a member of the serine/arginine (SR) protein superfamily that modulates gene expression by regulating mRNA splicing. The significance of TRA2B in cancer has received considerable attention in recent years, however, its specific role and molecular mechanisms in HCC remain unknown. This study aimed to analyze the expression of TRA2B in LIHC with the support of integrative bioinformatic analysis. The study conducted Kaplan-Meier and cox regression analyses and showed that the upregulated TRA2B was notably correlated with the dismal prognosis in HCC. TRA2B was identified as a potential proto-oncogene in HCC associated with poor prognosis. TRA2B expression in tumor tissues was found to be elevated using bioinformatics analysis. Following that, non-coding RNAs (ncRNA) related to TRA2B were extracted using series analysis. The CRNDE/LINC00511-miR-29c-3p axis was characterized as a potential upstream ncRNA-correlated signaling of TRA2B in HCC. Subsequently, the role of TRA2B in the tumor immune microenvironment (TIME) was investigated. In summary, this research provides novel insight into the potential role of TRA2B across various cancers and indicated that ncRNA-mediated overexpression of TRA2B is associated with the dismal prognosis in HCC.
- Open Access
- 26 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
CLEC11A as a potential biomarker for prognosis and response to immunotherapy in colon adenocarcinoma
Colon adenocarcinoma (COAD) ranks among the most prevalent malignancies. C-type lectin domain family 11 member A (CLEC11A) plays a role in the initiation and progression of various cancers. However, its involvement in COAD remains unclear. This study reveals that CLEC11A expression is significantly elevated in COAD tissues compared to normal counterparts. Moreover, higher CLEC11A levels correlate with advanced T and N stages as well as pathological stage. Survival analysis further indicates that elevated CLEC11A expression is linked to poor prognosis. Cox regression analysis identifies CLEC11A as an independent prognostic factor for unfavorable survival outcomes. Additionally, increased CLEC11A expression shows a positive association with immune cell infiltration and immune checkpoint markers. CLEC11A-related differentially expressed genes (DEGs) were also identified, and functional enrichment analyses were conducted to elucidate the biological roles of CLEC11A. Unsupervised cluster analysis of these DEGs across distinct subgroups was also performed. In conclusion, CLEC11A has the potential as both a prognostic biomarker and a modulator of immune responses in COAD.
- 26 September 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessCLEC11A as a potential biomarker for prognosis and response to immunotherapy in colon adenocarcinoma
Colon adenocarcinoma (COAD) ranks among the most prevalent malignancies. C-type lectin domain family 11 member A (CLEC11A) plays a role in the initiation and progression of various cancers. However, its involvement in COAD remains unclear. This study reveals that CLEC11A expression is significantly elevated in COAD tissues compared to normal counterparts. Moreover, higher CLEC11A levels correlate with advanced T and N stages as well as pathological stage. Survival analysis further indicates that elevated CLEC11A expression is linked to poor prognosis. Cox regression analysis identifies CLEC11A as an independent prognostic factor for unfavorable survival outcomes. Additionally, increased CLEC11A expression shows a positive association with immune cell infiltration and immune checkpoint markers. CLEC11A-related differentially expressed genes (DEGs) were also identified, and functional enrichment analyses were conducted to elucidate the biological roles of CLEC11A. Unsupervised cluster analysis of these DEGs across distinct subgroups was also performed. In conclusion, CLEC11A has the potential as both a prognostic biomarker and a modulator of immune responses in COAD.